
Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024
Description
Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024
DelveInsight’s, “Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Gastroesophageal Reflux Disease (GERD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Gastroesophageal Reflux Disease (GERD): Overview
Gastroesophageal reflux disease (GERD) is a chronic gastrointestinal disorder characterized by the regurgitation of gastric contents into the esophagus. It is one of the most commonly diagnosed digestive disorders in the US with a prevalence of 20%, resulting in a significant economic burden in direct and indirect costs and adversely affects the quality of life. Currently, there is no known cause to explain the development of GERD. Over the years, several risk factors have been identified and implicated in the pathogenesis of GERD. Motor abnormalities such as esophageal dysmotility causing impaired esophageal acid clearance, impairment in the tone of the lower esophageal sphincter (LES), transient LES relaxation, and delayed gastric emptying are included in the causation of GERD. The goals of managing GERD are to address the resolution of symptoms and prevent complications such as esophagitis, BE, and esophageal adenocarcinoma. Treatment options include lifestyle modifications, medical management with antacids and antisecretory agents, surgical therapies, and endoluminal therapies.
""Gastroesophageal Reflux Disease (GERD) - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Gastroesophageal Reflux Disease (GERD) pipeline landscape is provided which includes the disease overview and Gastroesophageal Reflux Disease (GERD) treatment guidelines. The assessment part of the report embraces, in depth Gastroesophageal Reflux Disease (GERD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Gastroesophageal Reflux Disease (GERD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Gastroesophageal Reflux Disease (GERD) R&D. The therapies under development are focused on novel approaches to treat/improve Gastroesophageal Reflux Disease (GERD).
This segment of the Gastroesophageal Reflux Disease (GERD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastroesophageal Reflux Disease (GERD) Emerging Drugs
- X842: Cinclus Pharma
- Zastaprazan: Onconic Therapeutics
Further product details are provided in the report……..
Gastroesophageal Reflux Disease (GERD): Therapeutic Assessment
This segment of the report provides insights about the different Gastroesophageal Reflux Disease (GERD) drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Gastroesophageal Reflux Disease (GERD)
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Gastroesophageal Reflux Disease (GERD): Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastroesophageal Reflux Disease (GERD) therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastroesophageal Reflux Disease (GERD) drugs.
Gastroesophageal Reflux Disease (GERD) Report Insights
- Gastroesophageal Reflux Disease (GERD) Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Gastroesophageal Reflux Disease (GERD) drugs?
- How many Gastroesophageal Reflux Disease (GERD) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastroesophageal Reflux Disease (GERD)?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Gastroesophageal Reflux Disease (GERD) therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastroesophageal Reflux Disease (GERD) and their status?
- What are the key designations that have been granted to the emerging drugs?
- Cinclus Pharma
- Onconic Therapeutics
- Renexxion
- Addpharma
- Trio Medicines
- Chong Kun Dang Pharmaceutical
- HK inno.N Corporation
- X842
- JP-1366
- Naronapride
- AD-214
- AD-213
- AD-212
- Ceclazepide
- CKD-382
- IN-C004
- IN-C005
- IN-C001
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Gastroesophageal Reflux Disease (GERD): Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Gastroesophageal Reflux Disease (GERD) – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Zastaprazan: Onconic Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- X842: Cinclus Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- IN-C005: HK inno.N
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Gastroesophageal Reflux Disease (GERD) Key Companies
- Gastroesophageal Reflux Disease (GERD) Key Products
- Gastroesophageal Reflux Disease (GERD)- Unmet Needs
- Gastroesophageal Reflux Disease (GERD)- Market Drivers and Barriers
- Gastroesophageal Reflux Disease (GERD)- Future Perspectives and Conclusion
- Gastroesophageal Reflux Disease (GERD) Analyst Views
- Gastroesophageal Reflux Disease (GERD) Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.